Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.

Ilya KisterRyan CurtinAmanda L PiquetTyler BorkoJinglan PeiBarbara L BanburyTamar E BaconAngie KimMichael TuenYogambigai VelmuruguSamantha NyovanieSean SelvaMarie I SamanovicMark J MulliganYury PatskovskyJessica PriestMark CabatinganRyan C WingerMichelle KrogsgaardGregg J Silverman

Published in: Annals of clinical and translational neurology (2024)

Humoral and cellular benefits of COVID-19 vaccination in B-cell-depleted MS patients were sustained for up to 2 years when booster doses were administered.

Keyphrases

sars cov
end stage renal disease
newly diagnosed
coronavirus disease
ejection fraction
chronic kidney disease
prognostic factors
mass spectrometry
ms ms
immune response
respiratory syndrome coronavirus
patient reported outcomes